

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-11 (cancelled).

12 (currently amended). A method of treatment by dialysis of a patient in need of such treatment, which comprises ~~the use of~~ subjecting said patient to dialysis using a dialyzing solution including a low molecular weight thrombin inhibitor.

13 (original). A method as claimed in Claim 12 wherein the dialysis is haemodialysis.

14 (new). A method as claimed in Claim 12 or Claim 13, wherein the thrombin inhibitor is a low molecular weight peptide-based thrombin inhibitor, a low molecular weight amino acid-based thrombin inhibitor, and/or a low molecular weight peptide analogue-based thrombin inhibitor, or a prodrug of any of these.

15 (new). A method as claimed in Claim 14, wherein the thrombin inhibitor is inogatran or melagatran, or a prodrug thereof.

16 (new). A method as claimed in Claim 14, wherein the thrombin inhibitor is melagatran or a prodrug thereof.

17 (new). A dialysing solution including a low molecular weight thrombin inhibitor.

18 (new). A solution as claimed in Claim 17, wherein the dialysis is haemodialysis.

19 (new). A solution as claimed in Claim 17 or Claim 18, wherein the thrombin inhibitor is a low molecular weight peptide-based thrombin inhibitor, a low molecular weight amino acid-based thrombin inhibitor, and/or a low molecular weight peptide analogue-based thrombin inhibitor, or a prodrug of any of these.

20 (new). A solution as claimed in Claim 19, wherein the thrombin inhibitor is inogatran or melagatran, or a prodrug thereof.

21 (new). A solution as claimed in Claim 19, wherein the thrombin inhibitor is melagatran, or a prodrug thereof.

22 (new). A process for the preparation of a dialysing solution as defined in Claim 17, which comprises admixing a formulation including a low molecular weight thrombin inhibitor (or prodrug thereof) and a dialysing solution.

23 (new). A process as claimed in Claim 22, wherein the dialysis is haemodialysis.

24 (new). A process as claimed in Claim 22 or Claim 23, wherein the thrombin inhibitor is a low molecular weight peptide-based thrombin inhibitor, a low molecular weight amino acid-based thrombin inhibitor, and/or a low molecular weight peptide analogue-based thrombin inhibitor, or a prodrug of any of these.

25 (new). A process as claimed in Claim 24, wherein the thrombin inhibitor is inogatran or melagatran, or a prodrug thereof.

26 (new). A process as claimed in Claim 24, wherein the thrombin inhibitor is melagatran or a prodrug thereof.

27 (new). A dialysis concentrate including a low molecular weight thrombin inhibitor.

28 (new). A concentrate as claimed in Claim 27 wherein the dialysis is haemodialysis.

29 (new). A concentrate as claimed in Claim 27 or Claim 28, wherein the thrombin inhibitor is a low molecular weight peptide-based thrombin inhibitor, a low molecular weight amino acid-based thrombin inhibitor, and/or a low molecular weight peptide analogue-based thrombin inhibitor, or a prodrug of any of these.

30 (new). A concentrate as claimed in Claim 29, wherein the thrombin inhibitor is inogatran or melagatran, or a prodrug thereof.

31 (new). A concentrate as claimed in Claim 29, wherein the thrombin inhibitor is melagatran or a prodrug thereof.

32 (new). A process for the preparation of a dialysis concentrate as defined in Claim 27, which comprises admixing a formulation including a low molecular weight thrombin inhibitor (or prodrug thereof) and a dialysis concentrate.

33 (new). A process as claimed in Claim 32, wherein the dialysis is haemodialysis.

34 (new). A process as claimed in Claim 32 or Claim 33, wherein the thrombin inhibitor is a low molecular weight peptide-based thrombin inhibitor, a low molecular weight amino acid-based thrombin inhibitor, and/or a low molecular weight peptide analogue-based thrombin inhibitor, or a prodrug of any of these.

35 (new). A process as claimed in Claim 34, wherein the thrombin inhibitor is inogatran or melagatran, or a prodrug thereof.

36 (new). A process as claimed in Claim 34, wherein the thrombin inhibitor is melagatran or a prodrug thereof.

37 (new). A kit of parts for use in dialysis including (a) a formulation including a low molecular weight thrombin inhibitor, and (b) a dialysis concentrate.

38 (new). A kit as claimed in Claim 37 wherein the dialysis is haemodialysis.

39 (new). A kit as claimed in Claim 37 or Claim 38, wherein the thrombin inhibitor is a low molecular weight peptide-based thrombin inhibitor, a low molecular weight amino acid-based thrombin inhibitor, and/or a low molecular weight peptide analogue-based thrombin inhibitor, or a prodrug of any of these.

40 (new). A kit as claimed in Claim 39, wherein the thrombin inhibitor is inogatran or melagatran, or a prodrug thereof.

41 (new). A kit as claimed in Claim 39, wherein the thrombin inhibitor is melagatran or a prodrug thereof.